Economic impact of therapeutic substitution of a brand selective serotonin reuptake inhibitor with an alternative generic selective serotonin reuptake inhibitor in patients with major depressive disorder;Impacto económico de la sustitución terapéutica de un inhibidor selectivo de la recaptación de serotonina (SSRI) de marca con alternativas genéricas en pacientes con desorden depresivo mayor

Annals of Pharmacotherapy

Volumn 45, Issue 4, 2011, Pages 441-451

  Wu, Eric Q ^a   Yu, Andrew P ^a   Lauzon, Veronique ^a   Ramakrishnan, Karthik ^a   Marynchenko, Maryna ^a   Ben Hamadi, Rym ^a   Blum, Steven ^b   Erder, M Haim ^c  

^a ANALYSIS GROUP   (United States)

^b FOREST RESEARCH INSTITUTE   (United States)

^c SHIRE   (United States)

Author keywords

Costs; Escitalopram; Major depressive disorder; Resource use; Selective serotonin reuptake inhibitors; Therapeutic substitution

Indexed keywords

CITALOPRAM; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ADULT; ARTICLE; CAUSE OF DEATH; COST CONTROL; DATA BASE; DRUG COST; EMERGENCY WARD; FEMALE; HEALTH CARE COST; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MENTAL HEALTH; OUTCOME ASSESSMENT; PRIORITY JOURNAL;

ADULT; ANTIDEPRESSIVE AGENTS; CITALOPRAM; COST-BENEFIT ANALYSIS; DEPRESSIVE DISORDER, MAJOR; DRUG SUBSTITUTION; DRUGS, GENERIC; EMERGENCY SERVICE, HOSPITAL; FEMALE; HEALTH CARE COSTS; HOSPITALIZATION; HUMANS; MALE; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 79955622677     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1P482     Document Type: Article

References (23)

1. Eaton WW, Martins SS, Nestadt G, et al. The burden of mental disorders. Epidemiol Rev 2008;30:1-14. DOI 10.1093/epirev/mxn011
2. Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003;289:3095-105. DOI 10.1001/jama.289.23.3095
3. Trivedi MH, Rush JA, Crismon ML, et al. Clinical results for patients with major depressive disorder in the Texas Medication Algorithm Project. Arch Gen Psychiatry 2004;61:669-80. DOI 10.1001/archpsyc.61.7.669
4. Greenberg PE, Kessler RC, Birnbaum HG, et al. The economic burden of depression in the United States: how did it change between 1990 and 2000? J Clin Psychiatry 2003;64:1465-75. DOI 10.4088/JCP. v64n1211
5. Goldstein BJ, Goodnick PJ. Selective serotonin reuptake inhibitors in the treatment of affective disorders-III. Tolerability, safety and pharmacoeconomics. J Psychopharmacol 1998;12:S55-87. DOI 10.1177/0269881198012003041
6. Agency for Healthcare Research and Quality. Medical Expenditure Panel Survey: statistical brief #163, February 2007. www. meps.ahrq.gov/ mepsweb/data_files/publications/st163/stat163.pdf (accessed 2009 Aug 8).
7. Pharmacy Times. Top 200 prescription drugs of 2009, May 11, 2010. www. pharmacytimes.com/issue/pharmacy/2010/May2010/RxFocusTopDrugs-0510 (accessed 2010 Oct 20).
8. Dunn JD, Cannon E, Mitchell MP, et al. Utilization and drug cost outcomes of a step-therapy edit for generic antidepressants in an HMO in an integrated health system. J Manag Care Pharm 2006;12:294-302.
9. Hodgkin D, Horgan CM, Garnick DW, et al. Management of access to branded psychotropic medications in private health plans. Clin Ther 2007;29:371-80. DOI 10.1016/j. clinthera.2007.02.011
10. Kelton CM, Rebelein RP, Heaton PC, et al. Differences in the cost of antidepressants across state Medicaid programs. J Ment Health Policy Econ 2008;11:33-47.
11. Panzer PE, Regan TS, Chiao E, et al. Implications of an SSRI generic step therapy pharmacy benefit design: an economic model in anxiety disorders. Am J Manag Care 2005;11:S370-9.
12. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 2009;373:746-58. DOI 10.1016/S0140-6736(09)60046-5
13. Sullivan PW, Valuck R, Saseen J, et al. A comparison of the direct costs and cost effectiveness of serotonin reuptake inhibitors and associated adverse drug reactions. CNS Drugs 2004;18:911-32. DOI 10.2165/00023210-200418130-00006
14. Wu EQ, Ben-Hamadi R, Yu AP, et al. Healthcare utilization and costs incurred by patients with major depression after being switched from escitalopram to another SSRI for nonmedical reasons. J Med Econ 2010;13: 314-23. DOI 10.3111/13696998.2010.488985
15. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-9. DOI 10.1016/0895-4356(92)90133-8
16. Zhang J, Yu KF. What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. JAMA 1998;280: 1690-1. DOI 10.1001/jama.280.19.1690
17. Boulenger JP, Huusom AK, Florea I, et al. A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patients. Curr Med Res Opin 2006;22:1331-41. DOI 10.1185/030079906X115513
18. Kasper S, Spadone C, Verpillat P, et al. Onset of action of escitalopram compared with other antidepressants: results of a pooled analysis. Int Clin Psychopharmacol 2006;21:105-10. DOI 10.1097/01. yic.0000194375.42589. c3
19. Lepola U, Wade A, Andersen HF. Do equivalent doses of escitalopram and citalopram have similar efficacy? A pooled analysis of two positive placebo-controlled studies in major depressive disorder. Int Clin Psychopharmacol 2004;19:149-55. DOI 10.1097/00004850-200405000-00005
20. Moore N, Verdoux H, Fantino B. Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder. Int Clin Psychopharmacol 2005;20:131-7. DOI 10.1097/00004850-200505000-00002
21. Greenberg PE. Does generic substitution always make sense? J Med Econ 2008;11:547-53. DOI 10.3111/13696990802371075
22. McCombs J. Managing antidepressant drug therapy in an evolving marketplace. Am J Manag Care 2004;10(6 suppl):S173-8.
23. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006;163:1905-17. DOI 10.1176/appi. ajp.163.11.1905